Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
HOUSTON, March 15, 2018 -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced that the Company will release its 2017 fourth quarter and full year financial results on Friday, March 23, 2018, before the U.S. financial markets open.
Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Date | Friday, March 23, 2018 | |||
| Time | 8:30 a.m. EDT | |||
| Toll free (U.S.) | (866) 394-2901 | |||
| International | (616) 548-5567 | |||
| Webcast (live and replay) | www.plxpharma.com under the ‘Investor Relations’ section. |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 8198566. The archived webcast will be available for 30 days via the aforementioned URL.
About Aspertec
Aspertec 325 mg is an FDA-approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric-coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing an sNDA for Aspertec 81 mg maintenance dose form.
About PLx Pharma Inc.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide effective and safe aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
